Expression of SerpinB3, a member of serine-protease inhibitor family, is associated with the carcinogenesis process as it determines resistance to apoptosis, induces cell proliferation and greater cell invasiveness. Furthermore, it leads to impaired immune surveillance and reduced chemosensitivity.
Recent studies have documented that SerpinB3 is expressed in primary liver tumors with poor prognosis, in more advanced stage of colon and pancreatic tumors, in tumors of the lung, esophagus, breast and ovary with poor response to chemotherapy, thus is a good candidate for targeted cancer therapy.
At present, compounds that are effective at reducing the expression of SerpinB3 in said tumor forms, are lacking.
The 1-piperidin propionic acid, inhibitor of SerpinB3 production, is proposed as a novel adjuvant drug in the treatment of different types of solid tumors overexpressing SerpinB3 and resistant to chemotherapy.